IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL5.50▼ 0.19% USD/MXN18.61▼ 0.09% USD/CLP975.74— 0.00% USD/COP 3,240 — 0.00% USD/PEN3.44▼ 0.07% USD/ARS 1,545 — 0.00% USD/UYU40.31▲ 3.23% USD/PYG6,358▲ 6.40% USD/BOB11.81▲ 0.77% USD/DOP60.61▲ 4.08% USD/CRC448.27▲ 2.01% USD/GTQ7.64▲ 3.17% USD/HNL26.88▲ 3.19% USD/NIO 36.62 — 0.00% USD/VES895.29▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.99▲ 2.78% USD/TTD6.72▲ 2.44% EUR/BRL6.13▼ 0.68% BRENT 98.32 ▲ 0.03% WTI 90.83 ▲ 0.34% IRON ORE 161.91 — — COPPER 6.24 ▼ 0.18% GOLD 4,075 ▼ 0.94% SILVER 51.94 ▼ 0.56% SOY 1,194 ▲ 1.08% CORN 441.50 ▲ 0.34% WHEAT 591.25 ▼ 1.34% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00% IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL 5.50 ▼ 0.19% USD/MXN 18.61 ▼ 0.09% USD/CLP 975.74 ▼ 0.09% USD/COP 3,240 — 0.00% USD/PEN 3.44 ▼ 0.07% USD/ARS 1,545 — 0.00% USD/UYU 40.31 ▲ 3.23% USD/PYG 6,358 ▲ 6.40% USD/BOB 11.81 ▲ 0.77% USD/DOP 60.61 ▲ 4.08% USD/CRC 448.27 ▲ 2.01% USD/GTQ 7.64 ▲ 3.17% USD/HNL 26.88 ▲ 3.19% USD/NIO 36.62 — 0.00% USD/VES 895.29 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.99 ▲ 2.78% USD/TTD 6.72 ▲ 2.44% EUR/BRL 6.13 ▼ 0.69% BRENT 98.32 ▲ 0.03% WTI 90.83 ▲ 0.34% IRON ORE 161.91 — — COPPER 6.24 ▼ 0.18% GOLD 4,075 ▼ 0.94% SILVER 51.94 ▼ 0.56% SOY 1,194 ▲ 1.08% CORN 441.50 ▲ 0.34% WHEAT 591.25 ▼ 1.34% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00%
since 2009
Sunday, November 8, 2026

Covid-19 Brazil

ButanVac: Brazil’s health regulator requests additional documents to authorize trials

By · · 2 min read

RIO DE JANEIRO, BRAZIL – The Brazilian Health Regulatory Agency (ANVISA) announced that after the technical analysis of documents and data submitted for authorization of human trials, the so-called clinical trials, of the Covid-19 ButanVac vaccine, developed by the Butantan Institute, it has requested the São Paulo immunization development center for additional documents and information.

The request was made on Monday, April 26th. In a note, the agency said that the “Butantan’s authorization request, sent on April 23rd, and the clinical trial protocol sent last Friday, April 23rd, are still incomplete and do not meet the technical requirements for authorizing clinical trials of vaccines in humans.”

1
Brazilian Health Regulatory Agency (ANVISA).
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The applications in trials relate to phases 1 and 2, the first in volunteers.

With the sending of the agency’s requirements, ANVISA’s analysis deadline is interrupted, once the agency depends on Butantan’s information to proceed with the technical analysis, says the report. In the same note, the agency listed 44 missing items in the requirements needed to secure authorization.

In a statement, the Butantan Institute said it was advised by ANVISA on Tuesday, April 27th, about the notes and that “it will maintain contact with the regulatory agency to enable the necessary clarifications to proceed with the authorization process for the ButanVac’s phases 1 and 2 clinical trials.”

The reference center stated that “it expects the regulatory agency to have the due sense of urgency and approve the beginning of trials as soon as possible so that the new vaccine, the first one to be produced in the country without the need to import active pharmaceutical ingredients (APIs), may be quickly made available to the Brazilian population.”

Source: Veja

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.